Inhibiting specific gene expression by short interfering RNA (siRNA) offers a new therapeutic
strategy to tackle many diseases, including cancer, metabolic disorders, and viral infections,
at the molecular level. The macromolecular and polar nature of siRNA hinders its cellular
access to exert its effect. Nanoparticulate delivery systems can promote efficient intracellular
delivery. Despite showing promise in many preclinical studies and potential in some clinical
trials, siRNA has poor delivery efficiency, which continues to demand innovations, from …